Email: cspc@cspc.cn
Media
News Center
Jan. 02
2025
SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Dec. 30
2024
LEUPRORELIN EXTENDED-RELEASE INJECTION (SYH9016) OBTAINS CLINICAL TRIAL APPROVAL
Dec. 23
SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Dec. 20
SEMAGLUTIDE LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL
SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
